Pioneers in Neuroscience

Biogen announces new virtual research study, in collaboration with Apple

Study to investigate the role Apple Watch and iPhone could play in monitoring cognitive performance and screening decline in cognitive health.


Driven by our commitment to patients and our passion for neuroscience, Biogen remains focused on furthering Alzheimer’s disease research and treatment. Visit our resource center for the latest information, news and stories about Alzheimer’s disease at Biogen.

Biogen updates delivered to your inbox
The Alzheimer’s Puzzle: Unlocking the Science 

From imaging that enables us to see amyloid and tau in the brain to determine whether potential therapeutics reach their targets, to one big leap of faith that antibodies can get into the brain, our scientists are not giving up on solving the Alzheimer’s puzzle.

Carving out space for innovation using biosimilars

Biosimilars treatments give us the opportunity to help more patients at a lower out-of-pocket for the patient. 2020 data shows that our anti-TNF biosimilars had an associated cost savings of 1.8 billion euros and treated approximately 220,000 patients until now.

1/13/21 4:06 PM EST
Biogen to Report Fourth Quarter and Full Year 2020 Financial Results February 3, 2021
View all news
Diversity, Equity and Inclusion

Biogen is committed to the power of diversity – in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us.


Thank you to the many front-line workers and organizations working tirelessly to help in these difficult days. Please find updates on Biogen’s response to COVID-19 here.

Where Science Meets Humanity

Science that transforms patient lives. Science that seeks to solve societal problems. Science that acts with purpose. Science that is inspired by the diversity and passion of our people. Discover where science meets humanity at Biogen.

Follow us on social media